nodes	percent_of_prediction	percent_of_DWPC	metapath
Indinavir—SLCO1A2—Chlorambucil—testicular cancer	0.123	0.147	CbGbCtD
Indinavir—ABCC1—Dactinomycin—testicular cancer	0.0661	0.0792	CbGbCtD
Indinavir—ABCC1—Epirubicin—testicular cancer	0.0479	0.0574	CbGbCtD
Indinavir—ABCC1—Vinblastine—testicular cancer	0.0414	0.0496	CbGbCtD
Indinavir—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0386	0.0462	CbGbCtD
Indinavir—CYP3A7—Ifosfamide—testicular cancer	0.0386	0.0462	CbGbCtD
Indinavir—ABCC1—Etoposide—testicular cancer	0.0373	0.0447	CbGbCtD
Indinavir—ABCC2—Carboplatin—testicular cancer	0.0329	0.0394	CbGbCtD
Indinavir—ABCC2—Vinblastine—testicular cancer	0.0307	0.0367	CbGbCtD
Indinavir—CYP3A5—Ifosfamide—testicular cancer	0.0289	0.0347	CbGbCtD
Indinavir—ABCC2—Cisplatin—testicular cancer	0.0281	0.0337	CbGbCtD
Indinavir—ABCC2—Etoposide—testicular cancer	0.0276	0.0331	CbGbCtD
Indinavir—ABCC1—Doxorubicin—testicular cancer	0.0254	0.0305	CbGbCtD
Indinavir—ABCC1—Methotrexate—testicular cancer	0.0247	0.0295	CbGbCtD
Indinavir—CYP2C19—Ifosfamide—testicular cancer	0.0233	0.028	CbGbCtD
Indinavir—SLCO1A2—Methotrexate—testicular cancer	0.022	0.0264	CbGbCtD
Indinavir—SLCO1B1—Methotrexate—testicular cancer	0.0208	0.0249	CbGbCtD
Indinavir—CYP2C9—Ifosfamide—testicular cancer	0.0194	0.0232	CbGbCtD
Indinavir—ABCC2—Doxorubicin—testicular cancer	0.0188	0.0226	CbGbCtD
Indinavir—ABCC2—Methotrexate—testicular cancer	0.0182	0.0219	CbGbCtD
Indinavir—ABCB1—Dactinomycin—testicular cancer	0.016	0.0191	CbGbCtD
Indinavir—CYP3A5—Etoposide—testicular cancer	0.0138	0.0166	CbGbCtD
Indinavir—CYP3A4—Ifosfamide—testicular cancer	0.0113	0.0135	CbGbCtD
Indinavir—ABCB1—Vinblastine—testicular cancer	0.00999	0.012	CbGbCtD
Indinavir—CYP2C9—Cisplatin—testicular cancer	0.00944	0.0113	CbGbCtD
Indinavir—CYP2D6—Vinblastine—testicular cancer	0.00942	0.0113	CbGbCtD
Indinavir—ABCB1—Cisplatin—testicular cancer	0.00916	0.011	CbGbCtD
Indinavir—ABCB1—Etoposide—testicular cancer	0.009	0.0108	CbGbCtD
Indinavir—ABCB1—Doxorubicin—testicular cancer	0.00614	0.00735	CbGbCtD
Indinavir—CYP3A4—Vinblastine—testicular cancer	0.00599	0.00717	CbGbCtD
Indinavir—ABCB1—Methotrexate—testicular cancer	0.00595	0.00712	CbGbCtD
Indinavir—CYP2D6—Doxorubicin—testicular cancer	0.00579	0.00693	CbGbCtD
Indinavir—CYP3A4—Etoposide—testicular cancer	0.00539	0.00646	CbGbCtD
Indinavir—CYP3A4—Doxorubicin—testicular cancer	0.00368	0.00441	CbGbCtD
Indinavir—Fatigue—Etoposide—testicular cancer	0.00014	0.000847	CcSEcCtD
Indinavir—Neuropathy peripheral—Epirubicin—testicular cancer	0.00014	0.000847	CcSEcCtD
Indinavir—Jaundice—Epirubicin—testicular cancer	0.000139	0.000842	CcSEcCtD
Indinavir—Pain—Etoposide—testicular cancer	0.000139	0.00084	CcSEcCtD
Indinavir—Constipation—Etoposide—testicular cancer	0.000139	0.00084	CcSEcCtD
Indinavir—Urinary tract infection—Epirubicin—testicular cancer	0.000139	0.00084	CcSEcCtD
Indinavir—Dysuria—Doxorubicin—testicular cancer	0.000138	0.000838	CcSEcCtD
Indinavir—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000138	0.000833	CcSEcCtD
Indinavir—Haemoglobin—Methotrexate—testicular cancer	0.000137	0.000833	CcSEcCtD
Indinavir—Haemorrhage—Methotrexate—testicular cancer	0.000137	0.000829	CcSEcCtD
Indinavir—Hepatitis—Methotrexate—testicular cancer	0.000137	0.000829	CcSEcCtD
Indinavir—Sweating—Epirubicin—testicular cancer	0.000137	0.000828	CcSEcCtD
Indinavir—Pollakiuria—Doxorubicin—testicular cancer	0.000137	0.000828	CcSEcCtD
Indinavir—Haematuria—Epirubicin—testicular cancer	0.000136	0.000824	CcSEcCtD
Indinavir—Dizziness—Ifosfamide—testicular cancer	0.000136	0.000823	CcSEcCtD
Indinavir—Pharyngitis—Methotrexate—testicular cancer	0.000136	0.000822	CcSEcCtD
Indinavir—Urinary tract disorder—Methotrexate—testicular cancer	0.000135	0.000818	CcSEcCtD
Indinavir—Hepatobiliary disease—Epirubicin—testicular cancer	0.000135	0.000817	CcSEcCtD
Indinavir—Weight increased—Doxorubicin—testicular cancer	0.000135	0.000816	CcSEcCtD
Indinavir—Urethral disorder—Methotrexate—testicular cancer	0.000134	0.000812	CcSEcCtD
Indinavir—Sinusitis—Epirubicin—testicular cancer	0.000134	0.00081	CcSEcCtD
Indinavir—Feeling abnormal—Etoposide—testicular cancer	0.000134	0.00081	CcSEcCtD
Indinavir—Hyperglycaemia—Doxorubicin—testicular cancer	0.000133	0.000809	CcSEcCtD
Indinavir—Nausea—Dactinomycin—testicular cancer	0.000133	0.000807	CcSEcCtD
Indinavir—Pneumonia—Doxorubicin—testicular cancer	0.000133	0.000804	CcSEcCtD
Indinavir—Gastrointestinal pain—Etoposide—testicular cancer	0.000133	0.000804	CcSEcCtD
Indinavir—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000131	0.000792	CcSEcCtD
Indinavir—Vomiting—Ifosfamide—testicular cancer	0.000131	0.000791	CcSEcCtD
Indinavir—Hypersensitivity—Cisplatin—testicular cancer	0.00013	0.00079	CcSEcCtD
Indinavir—Renal failure—Doxorubicin—testicular cancer	0.00013	0.000786	CcSEcCtD
Indinavir—Rash—Ifosfamide—testicular cancer	0.00013	0.000785	CcSEcCtD
Indinavir—Dermatitis—Ifosfamide—testicular cancer	0.000129	0.000784	CcSEcCtD
Indinavir—Erythema multiforme—Methotrexate—testicular cancer	0.000129	0.000783	CcSEcCtD
Indinavir—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000129	0.000783	CcSEcCtD
Indinavir—Urticaria—Etoposide—testicular cancer	0.000129	0.000781	CcSEcCtD
Indinavir—Haemoglobin—Epirubicin—testicular cancer	0.000129	0.000779	CcSEcCtD
Indinavir—Jaundice—Doxorubicin—testicular cancer	0.000129	0.000779	CcSEcCtD
Indinavir—Abdominal pain—Etoposide—testicular cancer	0.000128	0.000777	CcSEcCtD
Indinavir—Body temperature increased—Etoposide—testicular cancer	0.000128	0.000777	CcSEcCtD
Indinavir—Urinary tract infection—Doxorubicin—testicular cancer	0.000128	0.000777	CcSEcCtD
Indinavir—Haemorrhage—Epirubicin—testicular cancer	0.000128	0.000775	CcSEcCtD
Indinavir—Hepatitis—Epirubicin—testicular cancer	0.000128	0.000775	CcSEcCtD
Indinavir—Hypoaesthesia—Epirubicin—testicular cancer	0.000127	0.000772	CcSEcCtD
Indinavir—Asthenia—Cisplatin—testicular cancer	0.000127	0.00077	CcSEcCtD
Indinavir—Pharyngitis—Epirubicin—testicular cancer	0.000127	0.00077	CcSEcCtD
Indinavir—Sweating—Doxorubicin—testicular cancer	0.000126	0.000766	CcSEcCtD
Indinavir—Urinary tract disorder—Epirubicin—testicular cancer	0.000126	0.000766	CcSEcCtD
Indinavir—Haematuria—Doxorubicin—testicular cancer	0.000126	0.000762	CcSEcCtD
Indinavir—Connective tissue disorder—Epirubicin—testicular cancer	0.000126	0.000762	CcSEcCtD
Indinavir—Urethral disorder—Epirubicin—testicular cancer	0.000125	0.00076	CcSEcCtD
Indinavir—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000125	0.000756	CcSEcCtD
Indinavir—Sinusitis—Doxorubicin—testicular cancer	0.000124	0.00075	CcSEcCtD
Indinavir—Immune system disorder—Methotrexate—testicular cancer	0.000124	0.000748	CcSEcCtD
Indinavir—Chills—Methotrexate—testicular cancer	0.000123	0.000743	CcSEcCtD
Indinavir—Nausea—Ifosfamide—testicular cancer	0.000122	0.000739	CcSEcCtD
Indinavir—Diarrhoea—Cisplatin—testicular cancer	0.000121	0.000734	CcSEcCtD
Indinavir—Erythema multiforme—Epirubicin—testicular cancer	0.000121	0.000733	CcSEcCtD
Indinavir—Alopecia—Methotrexate—testicular cancer	0.000121	0.000732	CcSEcCtD
Indinavir—Hypersensitivity—Etoposide—testicular cancer	0.00012	0.000724	CcSEcCtD
Indinavir—Malnutrition—Methotrexate—testicular cancer	0.000119	0.000721	CcSEcCtD
Indinavir—Haemoglobin—Doxorubicin—testicular cancer	0.000119	0.000721	CcSEcCtD
Indinavir—Flushing—Epirubicin—testicular cancer	0.000119	0.00072	CcSEcCtD
Indinavir—Haemorrhage—Doxorubicin—testicular cancer	0.000118	0.000717	CcSEcCtD
Indinavir—Hepatitis—Doxorubicin—testicular cancer	0.000118	0.000717	CcSEcCtD
Indinavir—Hypoaesthesia—Doxorubicin—testicular cancer	0.000118	0.000714	CcSEcCtD
Indinavir—Pharyngitis—Doxorubicin—testicular cancer	0.000118	0.000712	CcSEcCtD
Indinavir—Urinary tract disorder—Doxorubicin—testicular cancer	0.000117	0.000709	CcSEcCtD
Indinavir—Dysgeusia—Methotrexate—testicular cancer	0.000117	0.000706	CcSEcCtD
Indinavir—Asthenia—Etoposide—testicular cancer	0.000116	0.000705	CcSEcCtD
Indinavir—Connective tissue disorder—Doxorubicin—testicular cancer	0.000116	0.000705	CcSEcCtD
Indinavir—Urethral disorder—Doxorubicin—testicular cancer	0.000116	0.000703	CcSEcCtD
Indinavir—Immune system disorder—Epirubicin—testicular cancer	0.000116	0.0007	CcSEcCtD
Indinavir—Back pain—Methotrexate—testicular cancer	0.000115	0.000698	CcSEcCtD
Indinavir—Chills—Epirubicin—testicular cancer	0.000115	0.000696	CcSEcCtD
Indinavir—Pruritus—Etoposide—testicular cancer	0.000115	0.000695	CcSEcCtD
Indinavir—Alopecia—Epirubicin—testicular cancer	0.000113	0.000685	CcSEcCtD
Indinavir—Vomiting—Cisplatin—testicular cancer	0.000113	0.000682	CcSEcCtD
Indinavir—Vision blurred—Methotrexate—testicular cancer	0.000112	0.00068	CcSEcCtD
Indinavir—Erythema multiforme—Doxorubicin—testicular cancer	0.000112	0.000678	CcSEcCtD
Indinavir—Rash—Cisplatin—testicular cancer	0.000112	0.000676	CcSEcCtD
Indinavir—Dermatitis—Cisplatin—testicular cancer	0.000112	0.000676	CcSEcCtD
Indinavir—Malnutrition—Epirubicin—testicular cancer	0.000111	0.000675	CcSEcCtD
Indinavir—Diarrhoea—Etoposide—testicular cancer	0.000111	0.000672	CcSEcCtD
Indinavir—Ill-defined disorder—Methotrexate—testicular cancer	0.00011	0.000669	CcSEcCtD
Indinavir—Anaemia—Methotrexate—testicular cancer	0.00011	0.000667	CcSEcCtD
Indinavir—Flushing—Doxorubicin—testicular cancer	0.00011	0.000666	CcSEcCtD
Indinavir—Flatulence—Epirubicin—testicular cancer	0.00011	0.000665	CcSEcCtD
Indinavir—Tension—Epirubicin—testicular cancer	0.000109	0.000662	CcSEcCtD
Indinavir—Dysgeusia—Epirubicin—testicular cancer	0.000109	0.000661	CcSEcCtD
Indinavir—Nervousness—Epirubicin—testicular cancer	0.000108	0.000656	CcSEcCtD
Indinavir—Back pain—Epirubicin—testicular cancer	0.000108	0.000653	CcSEcCtD
Indinavir—Malaise—Methotrexate—testicular cancer	0.000107	0.00065	CcSEcCtD
Indinavir—Dizziness—Etoposide—testicular cancer	0.000107	0.00065	CcSEcCtD
Indinavir—Muscle spasms—Epirubicin—testicular cancer	0.000107	0.000649	CcSEcCtD
Indinavir—Immune system disorder—Doxorubicin—testicular cancer	0.000107	0.000648	CcSEcCtD
Indinavir—Vertigo—Methotrexate—testicular cancer	0.000107	0.000648	CcSEcCtD
Indinavir—Chills—Doxorubicin—testicular cancer	0.000106	0.000644	CcSEcCtD
Indinavir—Nausea—Cisplatin—testicular cancer	0.000105	0.000637	CcSEcCtD
Indinavir—Vision blurred—Epirubicin—testicular cancer	0.000105	0.000636	CcSEcCtD
Indinavir—Alopecia—Doxorubicin—testicular cancer	0.000105	0.000634	CcSEcCtD
Indinavir—Cough—Methotrexate—testicular cancer	0.000104	0.000629	CcSEcCtD
Indinavir—Ill-defined disorder—Epirubicin—testicular cancer	0.000103	0.000626	CcSEcCtD
Indinavir—Vomiting—Etoposide—testicular cancer	0.000103	0.000625	CcSEcCtD
Indinavir—Malnutrition—Doxorubicin—testicular cancer	0.000103	0.000625	CcSEcCtD
Indinavir—Anaemia—Epirubicin—testicular cancer	0.000103	0.000624	CcSEcCtD
Indinavir—Agitation—Epirubicin—testicular cancer	0.000102	0.00062	CcSEcCtD
Indinavir—Rash—Etoposide—testicular cancer	0.000102	0.00062	CcSEcCtD
Indinavir—Dermatitis—Etoposide—testicular cancer	0.000102	0.000619	CcSEcCtD
Indinavir—Headache—Etoposide—testicular cancer	0.000102	0.000616	CcSEcCtD
Indinavir—Flatulence—Doxorubicin—testicular cancer	0.000102	0.000615	CcSEcCtD
Indinavir—Chest pain—Methotrexate—testicular cancer	0.000101	0.000614	CcSEcCtD
Indinavir—Arthralgia—Methotrexate—testicular cancer	0.000101	0.000614	CcSEcCtD
Indinavir—Myalgia—Methotrexate—testicular cancer	0.000101	0.000614	CcSEcCtD
Indinavir—Tension—Doxorubicin—testicular cancer	0.000101	0.000613	CcSEcCtD
Indinavir—Dysgeusia—Doxorubicin—testicular cancer	0.000101	0.000612	CcSEcCtD
Indinavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000101	0.00061	CcSEcCtD
Indinavir—Malaise—Epirubicin—testicular cancer	0.0001	0.000609	CcSEcCtD
Indinavir—Discomfort—Methotrexate—testicular cancer	0.0001	0.000607	CcSEcCtD
Indinavir—Nervousness—Doxorubicin—testicular cancer	0.0001	0.000607	CcSEcCtD
Indinavir—Vertigo—Epirubicin—testicular cancer	0.0001	0.000606	CcSEcCtD
Indinavir—Syncope—Epirubicin—testicular cancer	9.99e-05	0.000605	CcSEcCtD
Indinavir—Back pain—Doxorubicin—testicular cancer	9.97e-05	0.000604	CcSEcCtD
Indinavir—Muscle spasms—Doxorubicin—testicular cancer	9.91e-05	0.0006	CcSEcCtD
Indinavir—Palpitations—Epirubicin—testicular cancer	9.85e-05	0.000597	CcSEcCtD
Indinavir—Loss of consciousness—Epirubicin—testicular cancer	9.79e-05	0.000593	CcSEcCtD
Indinavir—Cough—Epirubicin—testicular cancer	9.72e-05	0.000589	CcSEcCtD
Indinavir—Anaphylactic shock—Methotrexate—testicular cancer	9.72e-05	0.000589	CcSEcCtD
Indinavir—Vision blurred—Doxorubicin—testicular cancer	9.72e-05	0.000589	CcSEcCtD
Indinavir—Nausea—Etoposide—testicular cancer	9.64e-05	0.000584	CcSEcCtD
Indinavir—Ill-defined disorder—Doxorubicin—testicular cancer	9.57e-05	0.000579	CcSEcCtD
Indinavir—Nervous system disorder—Methotrexate—testicular cancer	9.53e-05	0.000577	CcSEcCtD
Indinavir—Anaemia—Doxorubicin—testicular cancer	9.53e-05	0.000577	CcSEcCtD
Indinavir—Thrombocytopenia—Methotrexate—testicular cancer	9.51e-05	0.000576	CcSEcCtD
Indinavir—Arthralgia—Epirubicin—testicular cancer	9.49e-05	0.000575	CcSEcCtD
Indinavir—Myalgia—Epirubicin—testicular cancer	9.49e-05	0.000575	CcSEcCtD
Indinavir—Chest pain—Epirubicin—testicular cancer	9.49e-05	0.000575	CcSEcCtD
Indinavir—Agitation—Doxorubicin—testicular cancer	9.48e-05	0.000574	CcSEcCtD
Indinavir—Anxiety—Epirubicin—testicular cancer	9.45e-05	0.000573	CcSEcCtD
Indinavir—Skin disorder—Methotrexate—testicular cancer	9.44e-05	0.000572	CcSEcCtD
Indinavir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	9.42e-05	0.000571	CcSEcCtD
Indinavir—Hyperhidrosis—Methotrexate—testicular cancer	9.39e-05	0.000569	CcSEcCtD
Indinavir—Discomfort—Epirubicin—testicular cancer	9.37e-05	0.000568	CcSEcCtD
Indinavir—Malaise—Doxorubicin—testicular cancer	9.3e-05	0.000563	CcSEcCtD
Indinavir—Dry mouth—Epirubicin—testicular cancer	9.28e-05	0.000562	CcSEcCtD
Indinavir—Vertigo—Doxorubicin—testicular cancer	9.26e-05	0.000561	CcSEcCtD
Indinavir—Anorexia—Methotrexate—testicular cancer	9.26e-05	0.000561	CcSEcCtD
Indinavir—Syncope—Doxorubicin—testicular cancer	9.25e-05	0.00056	CcSEcCtD
Indinavir—Palpitations—Doxorubicin—testicular cancer	9.11e-05	0.000552	CcSEcCtD
Indinavir—Anaphylactic shock—Epirubicin—testicular cancer	9.09e-05	0.000551	CcSEcCtD
Indinavir—Oedema—Epirubicin—testicular cancer	9.09e-05	0.000551	CcSEcCtD
Indinavir—Loss of consciousness—Doxorubicin—testicular cancer	9.06e-05	0.000549	CcSEcCtD
Indinavir—Cough—Doxorubicin—testicular cancer	9e-05	0.000545	CcSEcCtD
Indinavir—Shock—Epirubicin—testicular cancer	8.95e-05	0.000542	CcSEcCtD
Indinavir—Nervous system disorder—Epirubicin—testicular cancer	8.92e-05	0.00054	CcSEcCtD
Indinavir—Thrombocytopenia—Epirubicin—testicular cancer	8.9e-05	0.000539	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Methotrexate—testicular cancer	8.85e-05	0.000536	CcSEcCtD
Indinavir—Skin disorder—Epirubicin—testicular cancer	8.83e-05	0.000535	CcSEcCtD
Indinavir—Hyperhidrosis—Epirubicin—testicular cancer	8.79e-05	0.000533	CcSEcCtD
Indinavir—Insomnia—Methotrexate—testicular cancer	8.79e-05	0.000532	CcSEcCtD
Indinavir—Chest pain—Doxorubicin—testicular cancer	8.78e-05	0.000532	CcSEcCtD
Indinavir—Myalgia—Doxorubicin—testicular cancer	8.78e-05	0.000532	CcSEcCtD
Indinavir—Arthralgia—Doxorubicin—testicular cancer	8.78e-05	0.000532	CcSEcCtD
Indinavir—Anxiety—Doxorubicin—testicular cancer	8.75e-05	0.00053	CcSEcCtD
Indinavir—Paraesthesia—Methotrexate—testicular cancer	8.73e-05	0.000529	CcSEcCtD
Indinavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	8.72e-05	0.000528	CcSEcCtD
Indinavir—Discomfort—Doxorubicin—testicular cancer	8.67e-05	0.000525	CcSEcCtD
Indinavir—Anorexia—Epirubicin—testicular cancer	8.67e-05	0.000525	CcSEcCtD
Indinavir—Dyspnoea—Methotrexate—testicular cancer	8.66e-05	0.000525	CcSEcCtD
Indinavir—Somnolence—Methotrexate—testicular cancer	8.64e-05	0.000523	CcSEcCtD
Indinavir—Dry mouth—Doxorubicin—testicular cancer	8.58e-05	0.00052	CcSEcCtD
Indinavir—Dyspepsia—Methotrexate—testicular cancer	8.55e-05	0.000518	CcSEcCtD
Indinavir—Decreased appetite—Methotrexate—testicular cancer	8.45e-05	0.000512	CcSEcCtD
Indinavir—Oedema—Doxorubicin—testicular cancer	8.41e-05	0.00051	CcSEcCtD
Indinavir—Anaphylactic shock—Doxorubicin—testicular cancer	8.41e-05	0.00051	CcSEcCtD
Indinavir—Gastrointestinal disorder—Methotrexate—testicular cancer	8.39e-05	0.000508	CcSEcCtD
Indinavir—Fatigue—Methotrexate—testicular cancer	8.38e-05	0.000508	CcSEcCtD
Indinavir—Pain—Methotrexate—testicular cancer	8.31e-05	0.000503	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Epirubicin—testicular cancer	8.29e-05	0.000502	CcSEcCtD
Indinavir—Shock—Doxorubicin—testicular cancer	8.28e-05	0.000501	CcSEcCtD
Indinavir—Nervous system disorder—Doxorubicin—testicular cancer	8.25e-05	0.0005	CcSEcCtD
Indinavir—Thrombocytopenia—Doxorubicin—testicular cancer	8.24e-05	0.000499	CcSEcCtD
Indinavir—Insomnia—Epirubicin—testicular cancer	8.23e-05	0.000498	CcSEcCtD
Indinavir—Skin disorder—Doxorubicin—testicular cancer	8.17e-05	0.000495	CcSEcCtD
Indinavir—Paraesthesia—Epirubicin—testicular cancer	8.17e-05	0.000495	CcSEcCtD
Indinavir—Hyperhidrosis—Doxorubicin—testicular cancer	8.13e-05	0.000493	CcSEcCtD
Indinavir—Dyspnoea—Epirubicin—testicular cancer	8.11e-05	0.000491	CcSEcCtD
Indinavir—Somnolence—Epirubicin—testicular cancer	8.08e-05	0.00049	CcSEcCtD
Indinavir—Anorexia—Doxorubicin—testicular cancer	8.02e-05	0.000486	CcSEcCtD
Indinavir—Feeling abnormal—Methotrexate—testicular cancer	8.01e-05	0.000485	CcSEcCtD
Indinavir—Dyspepsia—Epirubicin—testicular cancer	8.01e-05	0.000485	CcSEcCtD
Indinavir—Gastrointestinal pain—Methotrexate—testicular cancer	7.95e-05	0.000481	CcSEcCtD
Indinavir—Decreased appetite—Epirubicin—testicular cancer	7.91e-05	0.000479	CcSEcCtD
Indinavir—Gastrointestinal disorder—Epirubicin—testicular cancer	7.85e-05	0.000476	CcSEcCtD
Indinavir—Fatigue—Epirubicin—testicular cancer	7.84e-05	0.000475	CcSEcCtD
Indinavir—Constipation—Epirubicin—testicular cancer	7.78e-05	0.000471	CcSEcCtD
Indinavir—Pain—Epirubicin—testicular cancer	7.78e-05	0.000471	CcSEcCtD
Indinavir—Urticaria—Methotrexate—testicular cancer	7.72e-05	0.000468	CcSEcCtD
Indinavir—Abdominal pain—Methotrexate—testicular cancer	7.68e-05	0.000465	CcSEcCtD
Indinavir—Body temperature increased—Methotrexate—testicular cancer	7.68e-05	0.000465	CcSEcCtD
Indinavir—Musculoskeletal discomfort—Doxorubicin—testicular cancer	7.67e-05	0.000464	CcSEcCtD
Indinavir—Insomnia—Doxorubicin—testicular cancer	7.61e-05	0.000461	CcSEcCtD
Indinavir—Paraesthesia—Doxorubicin—testicular cancer	7.56e-05	0.000458	CcSEcCtD
Indinavir—Dyspnoea—Doxorubicin—testicular cancer	7.5e-05	0.000454	CcSEcCtD
Indinavir—Feeling abnormal—Epirubicin—testicular cancer	7.49e-05	0.000454	CcSEcCtD
Indinavir—Somnolence—Doxorubicin—testicular cancer	7.48e-05	0.000453	CcSEcCtD
Indinavir—Gastrointestinal pain—Epirubicin—testicular cancer	7.44e-05	0.00045	CcSEcCtD
Indinavir—Dyspepsia—Doxorubicin—testicular cancer	7.41e-05	0.000449	CcSEcCtD
Indinavir—Decreased appetite—Doxorubicin—testicular cancer	7.31e-05	0.000443	CcSEcCtD
Indinavir—Gastrointestinal disorder—Doxorubicin—testicular cancer	7.26e-05	0.00044	CcSEcCtD
Indinavir—Fatigue—Doxorubicin—testicular cancer	7.25e-05	0.000439	CcSEcCtD
Indinavir—Urticaria—Epirubicin—testicular cancer	7.22e-05	0.000438	CcSEcCtD
Indinavir—Constipation—Doxorubicin—testicular cancer	7.2e-05	0.000436	CcSEcCtD
Indinavir—Pain—Doxorubicin—testicular cancer	7.2e-05	0.000436	CcSEcCtD
Indinavir—Abdominal pain—Epirubicin—testicular cancer	7.19e-05	0.000435	CcSEcCtD
Indinavir—Body temperature increased—Epirubicin—testicular cancer	7.19e-05	0.000435	CcSEcCtD
Indinavir—Hypersensitivity—Methotrexate—testicular cancer	7.16e-05	0.000434	CcSEcCtD
Indinavir—Asthenia—Methotrexate—testicular cancer	6.97e-05	0.000422	CcSEcCtD
Indinavir—Feeling abnormal—Doxorubicin—testicular cancer	6.93e-05	0.00042	CcSEcCtD
Indinavir—Gastrointestinal pain—Doxorubicin—testicular cancer	6.88e-05	0.000417	CcSEcCtD
Indinavir—Pruritus—Methotrexate—testicular cancer	6.88e-05	0.000416	CcSEcCtD
Indinavir—Hypersensitivity—Epirubicin—testicular cancer	6.7e-05	0.000406	CcSEcCtD
Indinavir—Urticaria—Doxorubicin—testicular cancer	6.68e-05	0.000405	CcSEcCtD
Indinavir—Abdominal pain—Doxorubicin—testicular cancer	6.65e-05	0.000403	CcSEcCtD
Indinavir—Body temperature increased—Doxorubicin—testicular cancer	6.65e-05	0.000403	CcSEcCtD
Indinavir—Diarrhoea—Methotrexate—testicular cancer	6.65e-05	0.000403	CcSEcCtD
Indinavir—Asthenia—Epirubicin—testicular cancer	6.52e-05	0.000395	CcSEcCtD
Indinavir—Pruritus—Epirubicin—testicular cancer	6.43e-05	0.00039	CcSEcCtD
Indinavir—Dizziness—Methotrexate—testicular cancer	6.43e-05	0.000389	CcSEcCtD
Indinavir—Diarrhoea—Epirubicin—testicular cancer	6.22e-05	0.000377	CcSEcCtD
Indinavir—Hypersensitivity—Doxorubicin—testicular cancer	6.2e-05	0.000376	CcSEcCtD
Indinavir—Vomiting—Methotrexate—testicular cancer	6.18e-05	0.000374	CcSEcCtD
Indinavir—Rash—Methotrexate—testicular cancer	6.13e-05	0.000371	CcSEcCtD
Indinavir—Dermatitis—Methotrexate—testicular cancer	6.12e-05	0.000371	CcSEcCtD
Indinavir—Headache—Methotrexate—testicular cancer	6.09e-05	0.000369	CcSEcCtD
Indinavir—Asthenia—Doxorubicin—testicular cancer	6.04e-05	0.000366	CcSEcCtD
Indinavir—Dizziness—Epirubicin—testicular cancer	6.01e-05	0.000364	CcSEcCtD
Indinavir—Pruritus—Doxorubicin—testicular cancer	5.95e-05	0.000361	CcSEcCtD
Indinavir—Vomiting—Epirubicin—testicular cancer	5.78e-05	0.00035	CcSEcCtD
Indinavir—Nausea—Methotrexate—testicular cancer	5.77e-05	0.00035	CcSEcCtD
Indinavir—Diarrhoea—Doxorubicin—testicular cancer	5.76e-05	0.000349	CcSEcCtD
Indinavir—Rash—Epirubicin—testicular cancer	5.73e-05	0.000347	CcSEcCtD
Indinavir—Dermatitis—Epirubicin—testicular cancer	5.73e-05	0.000347	CcSEcCtD
Indinavir—Headache—Epirubicin—testicular cancer	5.7e-05	0.000345	CcSEcCtD
Indinavir—Dizziness—Doxorubicin—testicular cancer	5.56e-05	0.000337	CcSEcCtD
Indinavir—Nausea—Epirubicin—testicular cancer	5.4e-05	0.000327	CcSEcCtD
Indinavir—Vomiting—Doxorubicin—testicular cancer	5.35e-05	0.000324	CcSEcCtD
Indinavir—Rash—Doxorubicin—testicular cancer	5.31e-05	0.000321	CcSEcCtD
Indinavir—Dermatitis—Doxorubicin—testicular cancer	5.3e-05	0.000321	CcSEcCtD
Indinavir—Headache—Doxorubicin—testicular cancer	5.27e-05	0.000319	CcSEcCtD
Indinavir—Nausea—Doxorubicin—testicular cancer	5e-05	0.000303	CcSEcCtD
